Has Satish Shah, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,092,696 in general payments to Satish Shah, MD across 549 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Satish Shah, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Satish Shah, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Satish Shah, MD

Hematology & Oncology · Gettysburg, PANPI 1487679593

Payments from drug & device makers

$1,092,696in general payments, 2019–2025

Across 549 payments — averaging $1990.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Astrazeneca AB$332K
G1 Therapeutics, Inc.$189K
Theratechnologies Inc.$119K
AstraZeneca$93K
Merck$68K
AbbVie$63K
plus $228K from 54 others

$323,490in research payments, 2019–2025

Across 42 payments — averaging $7702.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

G1 Therapeutics, Inc.$183K
Regeneron$49K
AstraZeneca$34K
Celltrion, Inc.$27K
Astrazeneca AB$18K
Genentech, Inc.$9K
plus $5K from 1 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Astrazeneca AB	11	$332,142
G1 Therapeutics, Inc.	29	$188,521
Theratechnologies Inc.	11	$119,056
AstraZeneca	26	$93,053
Merck	88	$68,328
AbbVie	24	$62,895
Pharmacosmos Therapeutics Inc.	35	$37,333
Regeneron	6	$24,988
EMD Serono, Inc.	16	$23,857
Merck Healthcare Kgaa	5	$21,680
Astellas Pharma Global Development	4	$19,965
Janssen Research & Development, LLC	5	$15,715
Dova Pharmaceuticals	6	$14,497
Radius Health, Inc.	1	$12,600
Incyte Corporation	10	$7,548
Astrazeneca UK Limited	1	$6,594
Sanofi	8	$6,015
Sobi, Inc	5	$4,063
Ipsen Bioscience Inc.	1	$4,000
Tesaro, Inc.	9	$3,395
Genentech, Inc.	3	$3,270
Beigene USA, Inc.	7	$2,775
Fresenius Kabi USA, LLC	5	$2,199
GSK	6	$2,029
Amgen(2 entities)	15	$1,981
E.r. Squibb & Sons, L.L.C.	21	$1,817
ASD Specialty Healthcare, LLC	26	$1,457
Janssen Scientific Affairs, LLC	4	$1,240
Secura Bio, Inc.	2	$1,218
Adaptive Biotechnologies Corporation	3	$1,090
Athenex Pharmaceutical Division, LLC	1	$1,000
Bristol Myers Squibb	6	$877
Novartis	19	$561
Daiichi Sankyo Inc.	13	$424
Bayer	8	$381
Fennec Pharmaceuticals, Inc.	3	$335
Johnson & Johnson	13	$329
Regeneron Healthcare Solutions, Inc.	8	$306
Caris MPI, Inc.	5	$289
Seagen Inc.	5	$259
Mirati Therapeutics, Inc.	2	$222
Siemens Medical Solutions USA, Inc.	3	$221
Medtronic	1	$160
Celltrion USA Inc.	1	$150
Insmed, Inc.	1	$135
Biontech SE	1	$118
Servier Pharmaceuticals LLC	1	$109
Eisai Inc.	5	$105
Genentech USA, Inc.	6	$104
Astellas Pharma US Inc	4	$83
Intrinsiq Specialty Solutions, Inc.	1	$78
Takeda Pharmaceuticals U.S.A., Inc.	3	$78
Exelixis Inc.	2	$75
Pfizer	3	$73
Karyopharm Therapeutics Inc.	3	$67
Gilead(2 entities)	3	$63
Myovant Sciences Inc.	3	$47
Jazz Pharmaceuticals Inc.	2	$46
Kyowa Kirin, Inc.	2	$42
Sumitomo Pharma America, Inc.	2	$41

How this compares

$1,092,696 in reported general payments places this provider in the 90th percentile of 682 hematology & oncology providers in Pennsylvania.

See all hematology & oncology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$2,849,312

Medicare patients

523

Services billed

133,223

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Gettysburg

Diwakar DavarPittsburgh$21.6M
Jason LukePittsburgh$15M
Stephen BagleyPhiladelphia$13.1M
Leonard ApplemanPittsburgh$12.8M
Jing Zhou HouPittsburgh$11.9M
Taofeek OwonikokoPittsburgh$9.7M
Stephen SchusterPhiladelphia$9.5M
Pooja GhataliaPhiladelphia$8.3M
Corey LangerPhiladelphia$7.7M
Alfred GarfallPhiladelphia$7.6M

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →